Modulation of blood sugar level and lipid profiles by schiff base of (E)-3-(1H-imidazol-4-yl)-2-((2-oxoindolin-3-ylidene) amino) propanoicacid derivatives in streptozotocin-induced type II diabetic rats

Abstract

Background: Diabetes is a metabolic disease that disrupts metabolism of sugars and fats in the body. The aim of present study was to investigate the effect of isatin-schiff base derivatives on blood glucose and lipid levels in streptozotocin-induced type II diabetic rats. Materials and methods: Drugs (insulin, glibenclamide, Schiff base I and Schiff base II) were injected intraperitoneally for 14 days. After 14 days, blood samples were taken from all groups and blood glucose and lipid profiles were measured. Results: Streptozotocin injection significantly increased blood sugar, triglyceride, cholesterol and LDL, but significantly decreased blood HDL compared to the control group. Also, injection of insulin, glibenclamide, Schiff base I and different doses of Schiff base II (for 14 days) in the diabetic group significantly reduced blood sugar, triglycerides, cholesterol and LDL, but significantly increased blood HDL compared to the sham diabetic group. Injection of the lowest dose of Schiff base II (25 mg/kg) with glibenclamide (5 mg/kg) significantly reduced blood sugar compared to the control or glibenclamide group, but had no significant effect on triglyceride, cholesterol, HDL and LDL compared to the control, insulin or glibenclamide groups. Conclusion: These results indicate that the derivatives of E)) 3(H1-imidazole-4-yl) -2 ((2-oxindolin-3ylidine) amino) propanoic acid may be effective in the treatment of diabetes. The effect of Schiff base I and Schiff base II are probably due to the presence of isatin or imidazole ring and their antioxidant properties.